Axsome acquires global rights to PDE10A inhibitor balipodect from Takeda

Axsome Therapeutics, Inc.

Obtained exclusive worldwide rights to balipodect, a selective PDE10A inhibitor, from Takeda.
Balipodect completed a 164-patient Phase 2 trial in schizophrenia; safety profile established in over 360 individuals.
Axsome plans to start Phase 3-enabling activities for schizophrenia in 2026 and also target Tourette syndrome.
Takeda received an upfront payment and is eligible for development, regulatory, and commercial milestones plus royalties.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.